Pages that link to "Q30329521"

The following pages link to Clinical trials of HIV vaccines. (Q30329521):

Displaying 48 items.

• The Global HIV/AIDS Vaccine Enterprise: scientific strategic plan (Q21563445) (← links)
• Co-immunization with multimeric scaffolds and DNA rapidly induces potent autologous HIV-1 neutralizing antibodies and CD8+ T cells (Q28732043) (← links)
• Human Immunodeficiency Virus Type 1 Subtype B Ancestral Envelope Protein Is Functional and Elicits Neutralizing Antibodies in Rabbits Similar to Those Elicited by a Circulating Subtype B Envelope (Q29307502) (← links)
• Expression and Immunogenicity of Sequence-Modified Human Immunodeficiency Virus Type 1 Subtype BpolandgagpolDNA Vaccines (Q30332833) (← links)
• Sensitivity analyses comparing time-to-event outcomes only existing in a subset selected postrandomization and relaxing monotonicity (Q30501153) (← links)
• New recombinant vaccines based on the use of prokaryotic antigen-display systems. (Q33210092) (← links)
• On modeling HIV and T cells in vivo: assessing causal estimators in vaccine trials (Q33247446) (← links)
• Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables (Q33614495) (← links)
• Elimination of helminth infection restores HIV-1C vaccine-specific T cell responses independent of helminth-induced IL-10 (Q33699560) (← links)
• HIV neutralizing antibodies: clinical correlates and implications for vaccines (Q33703451) (← links)
• Multiclade human immunodeficiency virus type 1 envelope immunogens elicit broad cellular and humoral immunity in rhesus monkeys (Q33834916) (← links)
• Evaluating the immunogenicity of a disulfide-stabilized, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1 (Q33883887) (← links)
• Immunogen sequence: the fourth tier of AIDS vaccine design (Q34337482) (← links)
• Neutralizing antibodies against HIV -- back in the major leagues? (Q34712716) (← links)
• Unique V3 loop sequence derived from the R2 strain of HIV-type 1 elicits broad neutralizing antibodies (Q34999724) (← links)
• Broadly cross-neutralizing antibodies in HIV-1 patients with undetectable viremia (Q35077039) (← links)
• Conditional live virus as a novel approach towards a safe live attenuated HIV vaccine (Q35193454) (← links)
• ALVAC-HIV vaccines: clinical trial experience focusing on progress in vaccine development (Q35851797) (← links)
• The Trojan exosome hypothesis (Q35976953) (← links)
• Efficacy of AIDS vaccine strategies in nonhuman primates (Q36103593) (← links)
• T cell cross-reactivity and conformational changes during TCR engagement (Q36399643) (← links)
• Conservation of HIV-1 T cell epitopes across time and clades: validation of immunogenic HLA-A2 epitopes selected for the GAIA HIV vaccine (Q36467153) (← links)
• Multigene DNA priming-boosting vaccines protect macaques from acute CD4+-T-cell depletion after simian-human immunodeficiency virus SHIV89.6P mucosal challenge (Q36538907) (← links)
• Safety and immunogenicity of a Gag-Pol candidate HIV-1 DNA vaccine administered by a needle-free device in HIV-1-seronegative subjects (Q36628032) (← links)
• Structure and function of the HIV envelope glycoprotein as entry mediator, vaccine immunogen, and target for inhibitors (Q36856960) (← links)
• Identification of immunogenic HLA-B7 "Achilles' heel" epitopes within highly conserved regions of HIV (Q36910003) (← links)
• Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies (Q37033269) (← links)
• Sensitivity Analyses Comparing Time-to-Event Outcomes Existing Only in a Subset Selected Postrandomization (Q37035713) (← links)
• A simple one-step method for the preparation of HIV-1 envelope glycoprotein immunogens based on a CD4 mimic peptide (Q37102810) (← links)
• Viral sequence diversity: challenges for AIDS vaccine designs (Q37316023) (← links)
• Enhanced antibody responses to an HIV-1 membrane-proximal external region antigen in mice reconstituted with cultured lymphocytes (Q37730206) (← links)
• Novel adeno-associated virus vector vaccine restricts replication of simian immunodeficiency virus in macaques (Q37743813) (← links)
• Induction of HIV-specific functional immune responses by a multiclade HIV-1 DNA vaccine candidate in healthy Ugandans (Q38877415) (← links)
• The impact of envelope glycoprotein cleavage on the antigenicity, infectivity, and neutralization sensitivity of Env-pseudotyped human immunodeficiency virus type 1 particles (Q40414065) (← links)
• PROPORTIONAL HAZARDS MODELS WITH CONTINUOUS MARKS. (Q42041320) (← links)
• Highly efficient neutralization by plasma antibodies from human immunodeficiency virus type-1 infected individuals on antiretroviral drug therapy. (Q42228026) (← links)
• DNA vaccines expressing soluble CD4-envelope proteins fused to C3d elicit cross-reactive neutralizing antibodies to HIV-1. (Q44862450) (← links)
• Head-to-head comparison on the immunogenicity of two HIV/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV-1BX08 gp120 and HIV-1(IIIB) Gag-Pol-Nef proteins of clade B. (Q45235855) (← links)
• Expression of human immunodeficiency virus type 1 tat from a replication-deficient herpes simplex type 1 vector induces antigen-specific T cell responses (Q45413779) (← links)
• Efficient CD8+ T cell response to the HIV-env V3 loop epitope from multiple virus isolates by a DNA prime/vaccinia virus boost (rWR and rMVA strains) immunization regime and enhancement by the cytokine IFN-gamma (Q45597524) (← links)
• A conditionally replicating virus as a novel approach toward an HIV vaccine (Q45606075) (← links)
• Long-term safety analysis of preventive HIV-1 vaccines evaluated in AIDS vaccine evaluation group NIAID-sponsored Phase I and II clinical trials (Q47845658) (← links)
• A comparison of eight methods for the dual-endpoint evaluation of efficacy in a proof-of-concept HIV vaccine trial (Q50475666) (← links)
• Engineering immunogenic consensus T helper epitopes for a cross-clade HIV vaccine (Q51581860) (← links)
• Further progress on defining highly conserved immunogenic epitopes for a global HIV vaccine: HLA-A3-restricted GAIA vaccine epitopes (Q56999671) (← links)
• HIV vaccines: Biological and clinical considerations (Q60920348) (← links)
• Induction of CD8+ T cells to an HIV-1 antigen upon oral immunization of mice with a simian E1-deleted adenoviral vector (Q75325506) (← links)
• Generation and immunogenicity of novel HIV/AIDS vaccine candidates targeting HIV-1 Env/Gag-Pol-Nef antigens of clade C (Q79561534) (← links)